DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 969 filers reported holding DANAHER CORPORATION in Q2 2015. The put-call ratio across all filers is 0.93 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $2,193,798 | +8.4% | 8,779 | +8.3% | 0.16% | +1.9% |
Q1 2024 | $2,024,595 | +12.7% | 8,106 | +4.4% | 0.16% | +3.9% |
Q4 2023 | $1,796,910 | -17.0% | 7,766 | -11.0% | 0.15% | -29.0% |
Q3 2023 | $2,165,913 | +13.8% | 8,730 | +10.1% | 0.22% | +14.8% |
Q2 2023 | $1,903,329 | -7.0% | 7,929 | -2.3% | 0.19% | -11.3% |
Q1 2023 | $2,045,925 | -12.2% | 8,116 | -7.6% | 0.21% | -19.3% |
Q4 2022 | $2,331,525 | +8.9% | 8,783 | +6.0% | 0.26% | -6.7% |
Q3 2022 | $2,140,000 | +17.2% | 8,283 | +15.0% | 0.28% | +15.5% |
Q2 2022 | $1,826,000 | -9.6% | 7,201 | +4.5% | 0.24% | 0.0% |
Q1 2022 | $2,021,000 | -10.5% | 6,892 | +0.5% | 0.24% | -8.9% |
Q4 2021 | $2,257,000 | +14.3% | 6,859 | +5.8% | 0.27% | -2.2% |
Q3 2021 | $1,974,000 | +15.1% | 6,484 | +1.5% | 0.28% | +10.4% |
Q2 2021 | $1,715,000 | +33.2% | 6,390 | +11.7% | 0.25% | +19.1% |
Q1 2021 | $1,288,000 | +7.0% | 5,721 | +5.6% | 0.21% | -6.7% |
Q4 2020 | $1,204,000 | +7.1% | 5,419 | +3.9% | 0.22% | -8.6% |
Q3 2020 | $1,124,000 | +21.5% | 5,218 | -0.3% | 0.24% | +19.5% |
Q2 2020 | $925,000 | -25.0% | 5,233 | -41.0% | 0.20% | -0.5% |
Q1 2020 | $1,233,000 | +24.3% | 8,872 | +34.2% | 0.21% | +71.7% |
Q4 2019 | $992,000 | +14.7% | 6,613 | +8.6% | 0.12% | -9.8% |
Q3 2019 | $865,000 | +2.2% | 6,090 | +1.0% | 0.13% | -0.7% |
Q2 2019 | $846,000 | +31.0% | 6,027 | +20.8% | 0.13% | +17.5% |
Q1 2019 | $646,000 | +67.4% | 4,989 | +28.5% | 0.11% | +10.7% |
Q4 2018 | $386,000 | -1.0% | 3,881 | +3.5% | 0.10% | -7.2% |
Q3 2018 | $390,000 | +9.9% | 3,750 | 0.0% | 0.11% | -10.5% |
Q2 2018 | $355,000 | +0.6% | 3,750 | 0.0% | 0.12% | -3.1% |
Q1 2018 | $353,000 | +5.1% | 3,750 | +0.2% | 0.13% | -4.5% |
Q4 2017 | $336,000 | +9.4% | 3,743 | +0.3% | 0.13% | +5.5% |
Q3 2017 | $307,000 | +5.1% | 3,732 | +1.1% | 0.13% | -1.6% |
Q2 2017 | $292,000 | -10.7% | 3,693 | -5.8% | 0.13% | -10.4% |
Q1 2017 | $327,000 | +12.4% | 3,922 | +2.4% | 0.14% | -1.4% |
Q4 2016 | $291,000 | 0.0% | 3,829 | +0.8% | 0.15% | -23.2% |
Q3 2016 | $291,000 | -22.4% | 3,799 | 0.0% | 0.19% | -26.4% |
Q2 2016 | $375,000 | +6.5% | 3,799 | +0.7% | 0.26% | +13.2% |
Q1 2016 | $352,000 | -40.0% | 3,771 | -40.7% | 0.23% | -43.8% |
Q4 2015 | $587,000 | +229.8% | 6,364 | +199.3% | 0.41% | +230.1% |
Q3 2015 | $178,000 | +0.6% | 2,126 | +1.2% | 0.12% | +8.8% |
Q2 2015 | $177,000 | – | 2,100 | – | 0.11% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
WALTER & KEENAN WEALTH MANAGEMENT LLC /IN/ /ADV | 263,188 | $33,896,000 | 13.46% |
ARTHUR M. COHEN & ASSOCIATES, LLC | 263,188 | $33,896,000 | 13.46% |
Defender Capital, LLC. | 127,230 | $17,610,000 | 12.86% |
Eos Focused Equity Management, L.P. | 53,908 | $7,461,000 | 11.12% |
CORTLAND ASSOCIATES INC/MO | 419,035 | $57,999,000 | 10.88% |
Mirova US LLC | 477,368 | $66,072,000 | 8.75% |
Pactiv General Employee Benefit Trust | 579,300 | $80,181,000 | 8.58% |
Riverstone Advisors, LLC | 57,623 | $7,976,000 | 8.07% |
Eversept Partners, LP | 233,957 | $32,419,197 | 8.06% |
Third Point | 3,570,000 | $494,124,000 | 7.88% |